Compugen Ltd. Ordinary Shares (CGEN) Stock
Key stats
- Market cap
- $197.98M
- Price / Earnings ratio
- 5.4x
- EPS (TTM)
- $0.38
- Volume
- Loading
- 52-week high
- $3.24
- 52-week low
- $1.43
Source: third-party data provider, as of November 13, 2026
Compare with CGEN
Recent news

Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets
Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets
CGEN

All You Need to Know About Compugen (CGEN) Rating Upgrade to Buy
All You Need to Know About Compugen (CGEN) Rating Upgrade to Buy
CGEN

Are Medical Stocks Lagging Compugen (CGEN) This Year?
Are Medical Stocks Lagging Compugen (CGEN) This Year?
CGEN

Compugen Q2 Earnings Call Highlights
Compugen Q2 Earnings Call Highlights
CGEN
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 50.68
- MACD 12/26/9
- -0.04
- EMA 9 of MACD
- -0.07
- MACD histogram
- 0.03
- SMA 50
- $2.22
- Price below SMA 50
- EMA 50
- $2.16
- Price below EMA 50
- SMA 200
- $2.29
- Price below SMA 200
- EMA 200
- $2.17
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets
Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets
CGEN

All You Need to Know About Compugen (CGEN) Rating Upgrade to Buy
All You Need to Know About Compugen (CGEN) Rating Upgrade to Buy
CGEN

Are Medical Stocks Lagging Compugen (CGEN) This Year?
Are Medical Stocks Lagging Compugen (CGEN) This Year?
CGEN

Compugen Q2 Earnings Call Highlights
Compugen Q2 Earnings Call Highlights
CGEN

Compugen (CGEN) Reports Q2 Loss, Misses Revenue Estimates
Compugen (CGEN) Reports Q2 Loss, Misses Revenue Estimates
CGEN

Compugen Q1 Earnings Call Highlights
Compugen Q1 Earnings Call Highlights
CGEN

Compugen (CGEN) Reports Q1 Loss, Lags Revenue Estimates
Compugen (CGEN) Reports Q1 Loss, Lags Revenue Estimates
CGEN

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
CGEN

Gilead Sciences and Compugen strike commercialization deal for immunotherapy program
Gilead Sciences and Compugen strike commercialization deal for immunotherapy program
CGEN

Compugen stock rockets on anti-tumor drug deal with Gilead
Compugen stock rockets on anti-tumor drug deal with Gilead
CGEN
News tone: automated (AI) classification of the article's content, not a price prediction.
About Compugen Ltd. Ordinary Shares
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Eran Ophir Ph.D. | CEO, President & Director | 1978 |
| Dr. Anat Cohen-Dayag Ph.D. | Executive Chair | 1967 |
| Dr. Pierre Ferre Ph.D. | Chief Operating Officer | 1977 |
| Mr. David Silberman CPA | Chief Financial Officer | 1984 |
| Dr. Zurit Levine Ph.D. | Senior Vice President of Business Development | 1968 |
| Ms. Michelle Mahler M.D. | Chief Medical Officer | — |
| Ms. Lindsey Trickett | Head of Investor Relations and Corporate Communications | — |
| Mr. Eran Ben Dor | General Counsel & Corporate Secretary | — |
| Ms. Dorit Amitay | Vice President of Human Resources | 1968 |
| Rivka Schwartz | Vice President Research and Discovery | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 50.68
- MACD 12/26/9
- -0.04
- EMA 9 of MACD
- -0.07
- MACD histogram
- 0.03
- SMA 50
- $2.22
- Price below SMA 50
- EMA 50
- $2.16
- Price below EMA 50
- SMA 200
- $2.29
- Price below SMA 200
- EMA 200
- $2.17
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $4.00
- Average
- $4.00
- High
- $4.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -6.0 | -3.0 | -13.0 | +10.3 | +7.6 | -8.1 | -15.4 | +5.6 |



